Skip to main content
星昊医药 logo

星昊医药 — Investor Relations & Filings

Ticker · 920017 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2023-10-22 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920017

About 星昊医药

https://www.sunho.com.cn/

Beijing Sunho Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and commercialization of advanced pharmaceutical preparations. The company focuses on high-barrier drug delivery systems, including sustained-release, controlled-release, and complex injection technologies. Its core business encompasses the production of a diverse portfolio of chemical drugs and biological products, alongside comprehensive Contract Development and Manufacturing Organization (CDMO) services. Sunho Pharmaceutical operates modern, GMP-compliant production facilities designed to support the entire lifecycle of drug development, from pilot-scale testing to large-scale commercial manufacturing. By leveraging its proprietary formulation platforms, the company provides integrated solutions for complex dosage forms, catering to both domestic and international pharmaceutical markets.

Recent filings

Filing Released Lang Actions
第六届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 17th meeting of the 6th Board of Directors of Beijing Xinghao Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and specific decisions regarding adjustments to the 2023 equity incentive plan, including stock option price adjustments. The document is a board meeting resolution announcement rather than a full report or financial statement. It does not contain financial statements or detailed financial analysis, nor is it a transcript or presentation. It is not an annual or interim report, nor an earnings release. It is clearly a Board/Management Information announcement about decisions made by the board. The document length is under 5,000 characters and is a formal meeting resolution announcement, fitting the Board/Management Information (MANG) category.
2023-10-22 Chinese
第六届董事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 16th meeting of the 6th Board of Directors of Beijing Xinghao Pharmaceutical Co., Ltd. It includes details about the meeting date, attendance, and voting results. The key agenda item was the approval of the company's 2023 third quarter report, but the actual report is not included here; instead, it references that the report is disclosed on the Beijing Stock Exchange information platform. The document is short (889 characters) and serves as a meeting resolution announcement rather than the report itself. Therefore, it is best classified as a Board/Management Information (MANG) filing, which covers announcements of board decisions and management matters.
2023-10-19 Chinese
第七届监事会第六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a meeting resolution announcement from the Supervisory Board of Beijing Xinghao Pharmaceutical Co., Ltd. It details the meeting date, attendance, and the approval of the company's 2023 third quarter report. However, the actual third quarter report is not included; instead, it references that the report is disclosed on the Beijing Stock Exchange information platform with a separate announcement number. The document is short (781 characters) and serves as an official announcement of the meeting resolution and approval of the quarterly report, not the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than an Interim/Quarterly Report (IR).
2023-10-19 Chinese
2023年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2023 Third Quarter Report" of Beijing Xinghao Pharmaceutical Co., Ltd. It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and explanations of significant changes in financial data. The report covers the period ending September 30, 2023, and includes comprehensive financial figures and analysis for the first nine months of 2023 compared to the previous year. The document explicitly states it is a quarterly report and is unaudited. The length of the document (15,000 characters) and the presence of detailed financial statements confirm it is a full interim financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2023
2023-10-19 Chinese
关于2023年股权激励计划内幕信息知情人买卖公司股票情况的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report by Beijing Xinghao Pharmaceutical Co., Ltd. regarding insider trading activities related to the 2023 equity incentive plan. It details the investigation scope, procedures, and findings about insider stock transactions, confirming no misuse of insider information. The document references regulatory rules and internal policies, and it is a compliance and disclosure report about insider trading related to a specific equity incentive plan. It is not an annual report, earnings release, or financial statement. It is not a simple announcement of a report but a detailed self-inspection report. This fits the category of Regulatory Filings (RNS) as it is a regulatory compliance disclosure that does not fit other specific categories like Director's Dealing (DIRS) because it covers multiple insiders and is a self-inspection report rather than a single insider transaction report. The document length is 2360 characters, which is relatively short but contains substantive content about insider trading self-inspection. Therefore, the best classification is Regulatory Filings (RNS).
2023-10-16 Chinese
2023年第五次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2023 fifth extraordinary general meeting of shareholders of Beijing Xinghao Pharmaceutical Co., Ltd. It includes information about the meeting date, attendance, voting results on various proposals related to the 2023 equity incentive plan, and legal opinions confirming the validity of the meeting and voting procedures. The document does not contain financial statements or management discussion but focuses on the official voting results and meeting details. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4062 characters, which is sufficient to contain detailed voting results rather than just a brief announcement or a report publication notice. Therefore, the correct classification is DVA with high confidence.
2023-10-16 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.